mFOLFOX Clinical Trials

3 actively recruiting trials across 1 location

No change since May 2026

Also known as: Control group

Pipeline

Phase 1: 1Phase 2: 1Phase 2/3: 1

Top Sponsors

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest1
Innovent Biologics (Suzhou) Co. Ltd.1
InnoPharmax Inc.1

Indications

Cancer3
PDL-11
Gastroesophageal Adenocarcinoma1
Locally Advanced (Unresectable) or Metastatic Solid Tumors1
HER2 + Gastric Cancer1

Other2 trials

Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer

Phase 2/3

Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

Phase 2

Austin, Texas1 trial

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Next Oncology-Austin

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.